World's First Polynucleotide-FBDD Platform
World's First Polynucleotide-FBDD Platform
Polynucleotide-Targeting Drug Discovery Platform for Fragment-based Drug Discovery (FBDD)
Tags: Monash University, Australia, Healthcare & Lifesciences
This Drug Discovery Platform focuses on targeting polynucleotides and their protein complexes to address chronic diseases, cancer, and infectious diseases. It explores the largely untapped potential of non-coding genomic sequences and polynucleotide functions, expanding the druggable genome. With a library of small molecular weight compounds, it identifies novel therapeutics that bind polynucleotides to alter protein expression. The platform has demonstrated applications in creating treatments for conditions like spinal muscular atrophy. Its innovative approach offers broad therapeutic potential across various diseases.
IP Type or Form Factor: Patent Pending; Platform
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
